May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Effect of Triamcinolone Acetonide on in vitro Uveal Melanoma Cell Growth and VEGF Production
Author Affiliations & Notes
  • I. Homminga
    Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands
  • W. Maat
    Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands
  • C.J. M. Kröse
    Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands
  • M.J. Jager
    Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands
  • Footnotes
    Commercial Relationships  I. Homminga, None; W. Maat, None; C.J.M. Kröse, None; M.J. Jager, None.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 2225. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      I. Homminga, W. Maat, C.J. M. Kröse, M.J. Jager; Effect of Triamcinolone Acetonide on in vitro Uveal Melanoma Cell Growth and VEGF Production . Invest. Ophthalmol. Vis. Sci. 2006;47(13):2225.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Uveal melanoma patients often develop sight–threatening radiation retinopathy after radiotherapy. Triamcinolone acetonide is injected intravitreally to treat radiation retinopathy. However, living uveal melanoma cells may still be present in the eye after radiotherapy and the effect of triamcinolone acetonide on such remaining cells is not known. Therefore we studied the effect of triamcinolone acetonide on the growth of uveal melanoma cell lines in vitro. We also analyzed the effect of triamcinolone acetonide on the production of vascular endothelial growth factor A (VEGF–A), a pro–angiogenic molecule. Angiogenesis is an important pathological process involved in radiation retinopathy and inhibition of VEGF–A production might therefore form one of the working mechanisms of triamcinolone acetonide.

Methods: : Three uveal melanoma cell lines, OCM–1, 92–1 and Mel 285, were treated with 10µM and 100 µM triamcinolone acetonide suspensions. Viable cell numbers were estimated using a haemocytometer at four, six, eight and ten days after triamcinolone acetonide administration. In the supernatant of cells that had been exposed to triamcinolone acetonide for eight days, VEGF–A concentrations were determined in an ELISA.

Results: : All cell lines proliferated in vitro. Addition of the carrier (methanol) or triamcinolone acetonide did neither inhibit nor stimulate cell division. VEGF data will be presented at the meeting.

Conclusions: : Triamcinolone acetonide has no consistent inhibiting or stimulating effect on uveal melanoma cell growth, while the effect on VEGF production needs further analysis.

Keywords: oncology • melanoma • uvea 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×